Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient‐Derived Xenograft Models

Hepatology(2021)10.1002/hep.31919Source: DataRank Database

Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient‐Derived Xenograft Models is a research paper published in Hepatology (2021). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 1.38)OA: hybridTopics (50)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Maria Prates Rivas ORCID,Delphine Nicolle,Aurore Gorse,Ruhi Gulati ORCID,Meenasri Kumbaji ORCID

Live enrichment

PubMed:34037269 PMC:PMC8463483 OpenAlex:https://openalex.org/W3165369342

NCI NIH HHS

Grant: R01 CA159942

NIDDK NIH HHS

Grant: R01 DK102597

NIDDK NIH HHS

Grant: P30 DK078392

FWCI

1.38

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.31919

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.31919

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31919

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/hep.31919

publisherhttps://journals.lww.com/10.1002/hep.31919

Fields of Study

PARP inhibition in cancer therapyAdvanced Breast Cancer TherapiesLung Cancer Research StudiesAnimalsCell ProliferationCells, CulturedHepatoblastomaHumansKu AutoantigenLiver NeoplasmsMicePhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsRibosomal Protein S6 KinasesSignal TransductionTumor Suppressor Protein p53Xenograft Model Antitumor Assays

MeSH Terms

Poly(ADP-ribose) Polymerase InhibitorsPoly (ADP-Ribose) Polymerase-1Ku AutoantigenAnimalsCells, CulturedHumansLiver NeoplasmsPhthalazinesPiperazinesSignal TransductionTumor Suppressor Protein p53HepatoblastomaRibosomal Protein S6 KinasesXenograft Model Antitumor AssaysCell ProliferationMice

Keywords

HepatoblastomaPARP1OlaparibCancer researchCancerLiver cancerMedicineCancer cellBiologyHepatocellular carcinomaPoly ADP ribose polymeraseInternal medicineGenePolymeraseGenetics

Sustainable Development Goals

SDG 0: Good health and well-being